New Published Data Highlights Potential Cost-Savings of INPEFA® (sotagliflozin) for Heart Failure

By daniellenierenberg

New analysis of the pivotal Phase 3 SOLOIST-WHF trial provides additional evidence of positive economic impact on hospitals participating in various alternative payment models (APM)

Read the rest here:
New Published Data Highlights Potential Cost-Savings of INPEFA® (sotagliflozin) for Heart Failure

Related Post


categoriaCardiac Stem Cells commentoComments Off on New Published Data Highlights Potential Cost-Savings of INPEFA® (sotagliflozin) for Heart Failure | dataJuly 16th, 2024

About...

This author published 4793 posts in this site.

Share

FacebookTwitterEmailWindows LiveTechnoratiDeliciousDiggStumbleponMyspaceLikedin

Comments are closed.





Personalized Gene Medicine | Mesenchymal Stem Cells | Stem Cell Treatment for Multiple Sclerosis | Stem Cell Treatments | Board Certified Stem Cell Doctors | Stem Cell Medicine | Personalized Stem Cells Therapy | Stem Cell Therapy TV | Individual Stem Cell Therapy | Stem Cell Therapy Updates | MD Supervised Stem Cell Therapy | IPS Stem Cell Org | IPS Stem Cell Net | Genetic Medicine | Gene Medicine | Longevity Medicine | Immortality Medicine | Nano Medicine | Gene Therapy MD | Individual Gene Therapy | Affordable Stem Cell Therapy | Affordable Stem Cells | Stem Cells Research | Stem Cell Breaking Research

Copyright :: 2024